Osteoarthritis and associated pathology-clinical and pathogenetic associations
N.A. Shostak, N.G. Pravdyuk, A.A. Klimenko, A.A. Kondrashov, V.T. Timofeev
Pirogov Russian National Research Medical University, Moscow
Osteoarthritis (OA) is a group of diseases, based on the violation of all joint components. The main OA development mechanisms include reparative process disorders, “mechanical stress” and chronic inflammation in the joint. In OA, a concomitant pathology is 1.2 times more likely to be manifested; 2.5 times more often there is a combination of 3 diseases, i.e. there is a phenomenon called comorbidity. Comorbidity is the manifestation of an additional clinical condition that exists or arises in the setting of the current disease. In OA, the progression risk of a stroke, peptic ulcer and metabolic syndrome increases. The use of non-steroidal anti-inflammatory drugs in patients with OA increases the risk of complications from the gastrointestinal tract and the cardiovascular system. Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) have a more favorable safety profile, have their ow n analgesic effect and are involved in the catabolic inflammation suppression that underlies the OA progression. One of the drugs in this group is Alflutop®, the effectiveness and safety of which are shown in a number of preclinical and clinical studies. Alflutop® can be used to treat OA in patients with comorbid conditions.
Keywords: osteoarthritis, comorbidity, comorbid diseases, comorbid conditions, safety, Alflutop, SYSADOAs.
For citation: Shostak N.A., Pravdyuk N.G., Klimenko A.A. et al. Osteoarthritis and associated pathology-clinical and pathogenetic associations. RMJ. Medical Review. 2019;11(II):44–47.
2. Palazzo C., Ravaud J.-F., Papelard A. et al. The Burden of Musculoskeletal Conditions. PLoS One. 2014;9(3):e90633. DOI: 10.1371/journal.pone.0090633.
3. Шостак Н.А., Правдюк Н.Г. Боль в спине и коморбидность — диагностика, лечебная тактика. Амбулаторная хирургия. Стационарозамещающие технологии. 2016;3–4:63–64. [Shostak N.A., Pravdyuk N.G. Back pain and comorbidity — diagnosis, therapeutic tactics. Outpatient surgery. Stationary technology. 2016;3–4:63–64 (in Russ.)].
4. Nüesch E., Dieppe P., Reichenbach S. et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.
5. Roubille C., Coste J., Sellam J. et al. Cardiovascular Comorbidities have a deleterious impact on knee osteoarthritis prognosis at 5 years: data from the prospective KHOALA COHORT. Ann Rheum Dis. DOI: 10.1136/annrheumdis-2019-eular.3500.
6. Hall A.J., Stubbs B., Mamas M.A. et al. Association between osteoarthritis and cardiovascular disease: systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938–946. DOI: 10.1177/2047487315610663.
7. Koutroumpas A., Giannoukas A., Zintzaras E. et al. Erosive hand osteoarthritis is associated with subclinical atherosclerosis and endothelial dysfunction. Int J Biomed Sci. 2013;9(4):217–223.
8. Jonsson H., Helgadottir G.P., Aspelund T. et al. Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum Dis. 2009;68(11):1696–700. DOI: 10.1136/ard.2008.096289.
9. Haugen I.K., Ramachandran V.S., Misra D. et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study. Ann Rheum Dis. 2015;74(1):74–81. DOI: 10.1136/annrheumdis-2013-203789.
10. Courties A., Sellam J., Maheu E. et al. Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. RMD Open. 2017;3(1):e000344. DOI: 10.1136/rmdopen-2016-000344.
11. Atiquzzaman M., Karim M.E., Kopec J. et al. Role of Non‐Steroidal Anti‐Inflammatory Drugs (NSAID s) in the Association between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study. Arthritis Rheumatol. 2019;71(11):1835–1843. DOI: 10.1002/art.41027.
12. Cooper C., Chapurlat R., Al-Daghri N. et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019;36(Suppl 1):15–24. DOI: 10.1007/s40266-019-00660-1.
13. Bally M., Dendukuri N., Rich B. et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
14. Honvo G., Bannuru R.R., Bruyere O. et al. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommendations for the reporting of harms in studies assessing drugs to be used in osteoarthritis: a consensus statement from a working group on the safety of anti-osteoarthritis medications. Drugs Aging. 2019;36(1):145–159.
15. Шостак Н.А., Правдюк Н.Г. Костно-мышечные нарушения в практике интерниста-диагностика, подходы к лечению. Лечащий врач. 2017:12;68–73. [Shostak N.A., Pravdyuk N.G. Musculoskeletal disorders in the practice of the internist-diagnosis, treatment approaches. Therapist. 2017;12: 68–73 (in Russ.)].
16. Куксгауз И. А., Шекунова Е.В., Кашкин В.А. и др. Изучение гастропротективного эффекта препарата Алфлутоп на модели индуцированной диклофенаком гастропатии у крыс. Экспериментальная и клиническая гастроэнтерология. 2019;165(5):8–14. DOI: 10.31146/1682-8658-ecg-165-5-8-14. [Kuksgauz I.A., Shekunova E.V., Kashkin V.A. et al. Study of the gastroprotective effect of Alflutop on a model of diclofenac-induced gastropathy in rats. Experimental and clinical gastroenterology. 2019;165(5):8-14. DOI: 10.31146 / 1682-8658-ecg-165-5-8-14 (in Russ.)].
17. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике. М.: РНМОТ; 2016. [Management of patients with osteoarthritis and comorbidity in general medical practice. M.: RNMOT; 2016 (in Russ.)].
18. Алексеева Л.И., Таскина Е.А., Лила А.М. и др. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп в альтернирующем режиме по сравнению со стандартным режимом. Современная ревматология. 2019;13(3):51–59. [Alekseeva L.I., Taskina E.A., Lila A.M. et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop in alternating mode compared to the standard regimen. Modern rheumatology. 2019;13(3):51–59 (in Russ.)].
19. Swain S., Sarmanova A., Coupland C. et al. Comorbidities in Osteoarthritis: A systematic review and meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2019. DOI: 10.1002/acr.24008.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать